Furthermore, a Phase II, open-label, randomized trial was recently underway to assess the effects of olaparib alone and in combination with atezolizumab in HDR deficient locally advanced or metastatic non-HER2+ breast cancer, although it was recently suspended (NCT02849496) (245). This evidence concerns the gene ERBB2 and breast carcinoma.